Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aptinyx Reaches Milestones, Raises $70m To Develop NMDA Modulators

Executive Summary

Aptinyx – spun out of Naurex in 2015 after it was acquired by Allergan – closed a Series B venture capital round that brought in new investors with a long-term view, the ability to support a future IPO and experience with neuroscience drugs.


Related Content

Cerevel Launches With Pfizer's Early CNS Assets And $350m From Bain Capital
Finance Watch: Is The IPO Boom Making Anyone Nervous Yet?
Finance Watch: Six More IPO Filings As Three More Biopharmas Go Public In The US
Allergan paying $560m for Naurex; stays quiet on rumored generics sale to Teva


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts